# Mirum Pharmaceuticals Inc. (MIRM) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $100.90, market value $6.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Mirum Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 10.0×**. Each dollar of revenue is priced at 10.0×.
- **Price / book: 19.6×**. The shares trade at 19.6× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -3.7%** (5-yr avg -9.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -134.9%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -4.5%**. The company reported a net loss over the last twelve months.
- **Return on equity: -7.4%**. Return on equity is negative because earnings are negative.
- **Return on assets: -102.1%**. Each dollar of assets produces -102.1% of profit.

## Growth
- **Revenue growth (1 yr): 54.7%** (3-yr 89.1%/yr). Revenue grew 54.7% over the last year.
- **EPS growth (1 yr): 74.6%**. Earnings per share rose 74.6%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 2.67** (quick 2.67). Current assets cover the next year's liabilities 2.67 times.
- **Altman Z-score: 8.53**. A Z-score of 8.53 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Mirum Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (14 analysts). 14 analysts cover Mirum Pharmaceuticals Inc.; the consensus is strong_buy, with an average price target of $138.21 (+37% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 36.0%** (YTD 27.7%, 3-mo 7.9%). The shares are up 36.0% over twelve months including dividends.
- **From 52-week high: -22.4%** (59.6% above the low). Trading 22% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 48**. An RSI of 48 is neutral.
- **Beta (1 yr): 1.00** (volatility 46%). Beta of 1.00 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MIRM · Page: https://foliofundamentals.com/stocks/mirm

Not investment advice.